Share on StockTwits

NxStage Medical (NASDAQ:NXTM) SVP Winifred L. Swan sold 5,000 shares of the stock on the open market in a transaction dated Wednesday, May 14th. The shares were sold at an average price of $13.04, for a total value of $65,200.00. Following the sale, the senior vice president now directly owns 21,688 shares in the company, valued at approximately $282,812. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Shares of NxStage Medical (NASDAQ:NXTM) traded up 0.39% on Thursday, hitting $12.97. 318,090 shares of the company’s stock traded hands. NxStage Medical has a 1-year low of $8.77 and a 1-year high of $15.00. The stock has a 50-day moving average of $12.34 and a 200-day moving average of $12.02. The company’s market cap is $794.4 million.

NxStage Medical (NASDAQ:NXTM) last released its earnings data on Thursday, May 8th. The company reported ($0.09) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.11) by $0.02. The company had revenue of $72.20 million for the quarter, compared to the consensus estimate of $69.44 million. During the same quarter last year, the company posted ($0.08) earnings per share. NxStage Medical’s revenue was up 17.2% compared to the same quarter last year. On average, analysts predict that NxStage Medical will post $-0.40 earnings per share for the current fiscal year.

A number of analysts have recently weighed in on NXTM shares. Analysts at Canaccord Genuity reiterated a “buy” rating on shares of NxStage Medical in a research note on Friday, May 9th. They now have a $19.00 price target on the stock, down previously from $21.00. Separately, analysts at Wells Fargo & Co. downgraded shares of NxStage Medical from a “market perform” rating to an “underperform” rating in a research note on Tuesday, March 11th. Finally, analysts at Jefferies Group raised their price target on shares of NxStage Medical from $13.00 to $17.00 in a research note on Friday, February 28th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $16.83.

NxStage Medical, Inc (NASDAQ:NXTM) is a medical device company that develops, manufactures and markets products for the treatment of kidney failure, fluid overload and related blood treatments and procedures.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.